CN102626394A - Arginine ibuprofen granules and preparation method thereof - Google Patents
Arginine ibuprofen granules and preparation method thereof Download PDFInfo
- Publication number
- CN102626394A CN102626394A CN2012100679850A CN201210067985A CN102626394A CN 102626394 A CN102626394 A CN 102626394A CN 2012100679850 A CN2012100679850 A CN 2012100679850A CN 201210067985 A CN201210067985 A CN 201210067985A CN 102626394 A CN102626394 A CN 102626394A
- Authority
- CN
- China
- Prior art keywords
- arginine ibuprofen
- agent
- arginine
- correctives
- ibuprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to arginine ibuprofen granules. The arginine ibuprofen granules comprise arginine ibuprofen, one or more filling agents, one or more taste masking agents, an adhesive, a flavoring agent and a deodorant. The invention also provides a preparation method of the arginine ibuprofen granules. The arginine ibuprofen granules mask a spicy taste of arginine ibuprofen, realize good compliance of children, have short onset time and simple prescription composition, and comprise less types of auxiliary materials which are acquired easily, have low prices and avoid coating. The preparation method has simple processes, can be operated easily, avoids special equipment, has a short production period and a low cost, and is suitable for industrial production.
Description
Technical field
The present invention relates to the arginine Ibuprofen formulation art, be specifically related to a kind of arginine Ibuprofen granule and preparation method thereof.
Background technology
Traditional antipyretic analgesic ibuprofen is water-soluble hardly, and pharmacokinetic parameters Tmax value is 1.5～2h, and is the same with other oral NSAID (NSAID), and onset is slower relatively.Gondola Zambon S.P.A. company is according to practical situation; Solved this problem in 1986, developed the bonded salt of arginine Ibuprofen (CH673394):, changed the water-insoluble of ibuprofen because of arginic combination; Make absorption rate increase in the body, reach maximum plasma concentration (C
Max) time reduce, maximum plasma concentration increases, especially T
MaxValue reduces to 15～30min by 1.5～2h.
Ibuprofen contained in the arginine Ibuprofen granule can be by rapid absorption, and oral back 15～30min can reach maximum plasma concentration, and can bring into play pain relieving and antiphlogistic effect, and therapeutic effect is good.Use median dose, medication every day 1.2g mainly plays analgesic analgesic effect; Heavy dose has significant antiinflammatory action.It is mainly through little intestinal absorption; Plasma half-life is 1.5～2h; It is about 99% that protein binding rate reaches, mainly with non-activity metabolite form rapidly through RE, take the arginine Ibuprofen granule after; Ibuprofen and other metabolite can be drained in 24h fully, even also do not having the report of accumulating phenomenon between treatment over a long time.
Publication number is to disclose a kind of arginine ibuprofen tablet and preparation method thereof in the one Chinese patent application of CN 101390844A; This arginine ibuprofen tablet is prone to deliquescence and fails to cover the penetrating odor of medicine; Brought inconvenience for taking, especially pediatric pharmaceuticals inconvenience.
Publication number is to disclose a kind of preparation method of granules that contains the ibuprofen arginine compositions in the Chinese patent of CN 1237964C; Wherein adopted the step of coating to overcome the shortcoming that ibuprofen arginine is prone to the moisture absorption, covered the penetrating odor of medicine itself, still Duoed the step of coating than general granule; Production cycle is long; Cost is high, and melting is not good, and mouthfeel is poor.
Summary of the invention
The arginine Ibuprofen granule prepares defectives such as process is loaded down with trivial details, mouthfeel is poor, the children taking that do not suit in the prior art in order to overcome, and the purpose of this invention is to provide a kind of arginine Ibuprofen granule.
Arginine Ibuprofen granule provided by the invention is grouped into by following one-tenth by weight:
1 part of arginine Ibuprofen;
1～50 part of filler;
0.1～50 part of taste masked agent;
0.1～10 part of binding agent;
0.01～1 part of correctives;
0.01～1 part of flavoring agent.
Preferably, said arginine Ibuprofen granule is grouped into by following one-tenth by weight:
1 part of arginine Ibuprofen;
2～25 parts of filleies;
1～25 part of taste masked agent;
0.4～5 part of binding agent;
0.01～0.5 part of correctives;
0.01～0.5 part of flavoring agent.
Further preferably, said arginine Ibuprofen granule is grouped into by following one-tenth by weight:
1 part of arginine Ibuprofen;
2～10 parts of filleies;
2～10 parts of taste masked agent;
0.4～2.5 part of binding agent;
0.02～0.3 part of correctives;
0.01～0.1 part of flavoring agent.
Said filler is selected from one or more in lactose, sucrose, mannitol, the maltodextrin.
Said taste masked agent is selected from one or more in betacyclodextrin, hypromellose K4M, carboxymethylstach sodium, the 30 POVIDONE K 30 BP/USP 30.
Wherein, the preferred betacyclodextrin of taste masked agent is because its molecule has bigger void structure; In being enough to enclosed molecule is contained in, forming and divide an ascus, stop enclosed molecule to contact with the external world; Thereby can well shelter the bad mouthfeel and the abnormal smells from the patient of enclosed molecule, and can improve the stability of enclosed molecule.Behind Vander Waals power formation clathrate, dissolubility increase, the stability of medicine are improved, also can prevent the volatilization of volatile ingredient, adjustment release speed improves bioavailability, the zest and the toxic and side effects of reduction medicine.
Said binding agent is selected from the ethanol water of hypromellose K4M, the ethanol water or the ethanol water of 30 POVIDONE K 30 BP/USP 30.
Wherein, the concentration expressed in percentage by volume of ethanol water is 40～95%, and the mass percentage concentration of hypromellose K4M and 30 POVIDONE K 30 BP/USP 30 is preferably 2～10%.
Said correctives is selected from sodium cyclamate, aspartame or sucralose.
Said flavoring agent is an essence, is preferably orange essence or strawberry essence.
Preferably, said arginine Ibuprofen, filler, taste masked agent, correctives etc. are all smaller or equal to 100 orders.
Pungent mouthfeel is arranged owing to arginine Ibuprofen is water-soluble; Therefore; Filler that adds and correctives can only the regulator solution mouthfeel sugariness; Can not cover the acid of crude drug itself fully, the present invention is through the synergism of filler and correctives, and is aided with the mouthfeel after taste masked agent and flavoring agent come adjusting arginine Ibuprofen jointly water-soluble.The granule stable in properties of processing and do not have penetrating odor, melting is good, mouthfeel good, cost is low, especially is suitable for children taking.
The present invention also provides the method for preparing of each said arginine Ibuprofen granule of above technical scheme.
Said method comprises: at first with correctives and filler mix homogeneously, again with gained mixture and arginine Ibuprofen, taste masked agent mix homogeneously, add binding agent then and granulate, promptly get with the flavoring agent mixing more at last.
Wherein, said solid material such as arginine Ibuprofen, filler, taste masked agent, correctives etc. were crossed 100 mesh sieves before using.
Preferably, equivalent multiplication mixing method is adopted in mixing of correctives and filler, and each blended time is 15～50min; Correctives and filler gained mixture and arginine Ibuprofen, blended time of taste masked agent are 20～50min; Last and the blended time of flavoring agent is 1～10min.
Said pelletization is: adds binding agent and processes soft material, adopt 18 mesh sieves to granulate, and drying, last 16 mesh sieve granulate promptly get.
Said baking temperature is 50～90 ℃, preferred 60～80 ℃; Be 1～5h drying time.
Said arginine Ibuprofen granule packing specification is: 200mg/ bag (in ibuprofen, following specification is all in ibuprofen weight).The particulate consumption usage of arginine Ibuprofen: adult and patient more than 12 years old, common oral dose: 0.2g (1 bag), 3～4 times on the one, medicine is put into water tumbler, add an amount of warm water, be mixed into and can take after medicinal liquid dissolves fully.(medicine) being taken before meal is more rapid with the onset of these article, and generally every day, dosage was no more than 1.2g (promptly 6 bags, the 200mg/ bag), or under doctor's guidance, uses.The child should be in medication under the physician guidance below 12 years old.
Technical scheme provided by the invention has the following advantages:
1) arginine Ibuprofen granule safety and stability provided by the invention can be dissolved very soon, exists with liquid condition, can alleviate rapidly because of pain, joint and desmodynia, toothache, backache, headache, dysmenorrhea that wound causes, and the heating that causes of influenza.
2) the present invention comes enclose to shelter the pungent mouthfeel and the easy moisture absorption phenomenon of arginine Ibuprofen itself through employing taste masked agent especially betacyclodextrin; And can increase the stability of crude drug; Improve dissolubility and bioavailability, need not the shortcoming that coating both can have been covered the bad mouthfeel of crude drug, penetrating odor and the easy moisture absorption.
3) the present invention writes out a prescription and forms simply, supplementary product kind is few, be easy to get and inexpensive, need not coating, the preparation process is simple, and is easy to operate, need not special installation, with short production cycle, cost is low, is suitable for suitability for industrialized production.
4) gained arginine Ibuprofen granule of the present invention dissolves rapidly, forms clear solution in water, and glutinous not oiliness, mouthfeel is sweet, is convenient to take, and is accepted more easily.Child's compliance is good, and is rapid-action, and can avoid the child to swallow the danger of solid drugs, is more suitable for pediatric pharmaceuticals.
Description of drawings
Fig. 1 is the process chart of arginine Ibuprofen process for producing granula according to the invention.
The specific embodiment
Following examples are used to explain the present invention, but are not used for limiting scope of the present invention.
Embodiment 1
The screening process of arginine Ibuprofen granule prescription according to the invention is following:
(1), filler screening
The arginine Ibuprofen water solublity is better, but water-soluble pungent mouthfeel is arranged, and filler is observed melting and the product mouthfeel changes situation so add in the prescription.The selection result is seen table 1.
Table 1 filler screening (unit: g is with the packing of 200mg/ bag)
Conclusion: because arginine Ibuprofen is very easily water-soluble, water-soluble have pungent mouthfeel, so add the good and pleasantly sweet filler of dissolubility.But the filler that adds can only be used for the sugariness of excipient and regulator solution mouthfeel, can not cover the acid of crude drug itself fully.Even add the high-intensity sweeteners sodium cyclamate, the sugariness of sucrose solution is multiplied, also can't improve the acid of crude drug itself.So filler preferably sucrose in the arginine Ibuprofen, be benchmark with the sucrose consumption of writing out a prescription in 4, wouldn't add other sweeting agent, other screens the mouthfeel of other adjuvant and the composite adjusting product of sucrose.
(2), taste masked agent screening
Owing to use separately the sweeting agent that has the filler of sweet taste or add high sugariness in addition that the mouthfeel of product is improved, thus in the present invention's prescription in addition other adjuvants of interpolation be used to regulate mouthfeel.The present invention adopts the mouthfeel of taste masked agent and the composite adjusting product of filler, and table 2 is seen in taste masked agent screening.The strong flavor principle of taste masked agent is: 1, solution viscosity increases, and both can stop medicine to spread to taste bud, can disturb the sense of taste of taste bud again; 2, hole, a cave of molecule intermediate formation, hole, cave have unique bag connection function, can form bag access node compound with many materials, thus the nature and flavor of masking agents itself.
Table 2 taste masked agent screening (unit: g is with the packing of 200mg/ bag)
Conclusion: filler and taste masked agent are used and rectify flavor in the prescription, and effect is more satisfactory, and wherein writing out a prescription 10,14,15 does not all have tangible pungent sense; But 10 solution of writing out a prescription have tangible floccule, the solution of formation also show slightly sticky and aftertaste puckery slightly, prescription 14,15 liquid are clearly transparent, do not have a pungent sense; But 14 aftertaste of writing out a prescription are puckery slightly, think that relatively afterwards prescription 15 is even more ideal, and melting speed is very fast; Sticking not oiliness, more acceptant.But mouthfeel is sweetless, and taste is flat, so screen correctives in addition, flavoring agent is regulated the product mouthfeel.
(3), correctives and flavoring agent screening
Owing to use filler and taste masked agent can't make product solution good to eat, sweet, be used to regulate mouthfeel so add other adjuvant in the present invention's prescription in addition, increase user's compliance.The present invention adopts correctives and flavoring agent to work in coordination with the mouthfeel of regulating product, and table 3 is seen in the correctives screening, and table 4 is seen in the flavoring agent screening.The strong flavor principle of correctives, flavoring agent is: the sweeting agent or the essence that add high sugariness make solution fragrant and sweet good to eat; The general employing synthesized or semisynthetic sweeting agent or essence; Share with filler, the mouthfeel after adjusting arginine Ibuprofen granule is water-soluble, effect is very good.
Table 3 correctives screening (unit: g is with the packing of 200mg/ bag)
Table 4 flavoring agent screening (unit: g is with the packing of 200mg/ bag)
Conclusion: the correctives sucralose can produce the collaborative effect that increases sweet taste with filler sucrose in the prescription; Thereby improve the product solution sweetness value; And sucralose is the derivant of sucrose, and the sweet taste model of action is similar with sucrose with the persistent period, and sugariness is big, characteristic good; Stable in properties, dissolubility are big and do not have unhappy aftertaste in aqueous solution, thus preferably with sucralose as correctives.In prescription, when adopting sucrose and sucralose as adjuvant simultaneously, can also reduce the consumption of sucrose, both practice thrift raw material, and can also play good sweet taste effect, as write out a prescription in 18, the sucrose amount is reduced to 160g, also can reach similar effect.
(4), binding agent screening
Said arginine Ibuprofen granule has certain particle and hardness; The present invention adopts 50% ethanol water of 2% hypromellose K4M, 50% ethanol water of 8% polyvidon K30; The ethanol water of 40%～95% volumetric concentration is as binding agent; Preparation arginine Ibuprofen granule makes product have certain particle and hardness.Table 5 is seen in the binding agent screening.
Table 5 binding agent screening (unit: g is with the packing of 200mg/ bag)
Conclusion: prescription 24,25 gained arginine Ibuprofen granule yield are higher, and hardness is suitable, and are loose and can be soluble in water rapidly; But 24 soft materials of writing out a prescription are more sticking, are difficult for granulating, and the 26 granule yield of writing out a prescription are lower; Hardness is relatively poor, thus the present invention most preferably 70% ethanol water be binding agent.
Embodiment 2
Arginine Ibuprofen, sucrose, betacyclodextrin, sodium cyclamate are crossed 100 mesh sieves respectively, subsequent use.Take by weighing the raw material of following recipe quantity:
Sodium cyclamate is adopted equivalent multiplication method mix homogeneously (at every turn mixing 20min) with sucrose in about 1: 5 ratio; The mixture that obtains, again with arginine Ibuprofen, betacyclodextrin mix homogeneously (mixing 30min), (it is in 50% the ethanol water that hypromellose K4M is dissolved in concentration expressed in percentage by volume to add 2% hypromellose K4M50% ethanol water then; Wherein the mass percentage concentration of hypromellose K4M is 2%) process soft material; Adopt 18 mesh sieves to granulate, the back 60 ℃ of about 2h of forced air drying that granulate adopt 16 mesh sieve granulate; The granule that obtains is mixed about 3min with orange essence; Promptly obtain the arginine Ibuprofen granule, after the assay was approved, be distributed into the 200mg/ bag.
Embodiment 3
Arginine Ibuprofen, mannitol, hypromellose K4M, aspartame are crossed 100 mesh sieves respectively, subsequent use.
Take by weighing the raw material of following recipe quantity:
Aspartame is adopted equivalent multiplication method mix homogeneously (at every turn mixing 30min) with mannitol in about 1: 5 ratio, and the mixture that obtains is again with arginine Ibuprofen, hypromellose K4M mix homogeneously (mixing 20min); Adding concentration expressed in percentage by volume then is that 70% ethanol water is processed soft material; Adopt 18 mesh sieves to granulate, the back 60 ℃ of about 2h of forced air drying that granulate adopt 16 mesh sieve granulate; The granule that obtains is mixed about 2min with strawberry essence; Promptly obtain the arginine Ibuprofen granule, after the assay was approved, be distributed into the 200mg/ bag.
Embodiment 4
Arginine Ibuprofen, lactose, betacyclodextrin, sucralose are crossed 100 mesh sieves respectively, subsequent use.
Take by weighing the raw material of following recipe quantity:
Sucralose is adopted equivalent multiplication method mix homogeneously (at every turn mixing 20min) with lactose in about 1: 5 ratio, and the mixture that obtains is again with arginine Ibuprofen, betacyclodextrin mix homogeneously (mixing 30min); Add then 8%,PVP,K30 50% ethanol water (with 30 POVIDONE K 30 BP/USP 30 dissolve in concentration expressed in percentage by volume be make in 50% ethanol water solution, the mass percentage concentration of 30 POVIDONE K 30 BP/USP 30 is 8%) process soft material, adopt 18 mesh sieves to granulate; Granulate the back at 70 ℃ of about 3h of forced air drying; Adopt 16 mesh sieve granulate, the granule that obtains is mixed about 3min with orange essence, promptly obtain the arginine Ibuprofen granule; After the assay was approved, be distributed into the 200mg/ bag.
Embodiment 5
Arginine Ibuprofen, maltodextrin, betacyclodextrin, sucralose are crossed 100 mesh sieves respectively, subsequent use.
Take by weighing the raw material of following recipe quantity:
Sucralose is adopted equivalent multiplication method mix homogeneously (at every turn mixing 20min) with maltodextrin in about 1: 5 ratio, and the mixture that obtains is again with arginine Ibuprofen, betacyclodextrin mix homogeneously (mixing 30min); Adding concentration expressed in percentage by volume then is that 90% ethanol water is processed soft material; Adopt 18 mesh sieves to granulate, 16 mesh sieve granulate are adopted at 60 ℃ of about 2h of forced air drying in the back of granulating; The granule that obtains is mixed about 3min with orange essence; Promptly obtain the arginine Ibuprofen granule, after the assay was approved, be distributed into the 200mg/ bag.
Embodiment 6
Arginine Ibuprofen, sucrose, betacyclodextrin, sucralose are crossed 100 mesh sieves respectively, subsequent use.
Take by weighing the raw material of following recipe quantity:
Sucralose is adopted equivalent multiplication method mix homogeneously (at every turn mixing 35min) with sucrose in about 1: 5 ratio, and the mixture that obtains is again with arginine Ibuprofen, betacyclodextrin mix homogeneously (mixing 20min); Adding concentration expressed in percentage by volume then is that 70% ethanol water is processed soft material; Adopt 18 mesh sieves to granulate, 16 mesh sieve granulate are adopted at 55 ℃ of about 2h of forced air drying in the back of granulating; The granule that obtains is mixed about 3min with orange essence; Promptly obtain the arginine Ibuprofen granule, after the assay was approved, be distributed into the 200mg/ bag.
Comparative Examples 1
Except not doubling his cyclodextrin in the prescription, remaining is operated with embodiment 2.
Comparative Examples 2
Except not adding hypromellose K4M in the prescription, remaining is operated with embodiment 3.
Comparative Examples 3
Except not doubling his cyclodextrin in the prescription, remaining is operated with embodiment 4.
Comparative Examples 4
Except not adding sucralose in the prescription, remaining is operated with embodiment 6.
Comparative Examples 5
Publication number is to disclose a kind of particulate method for preparing that contains the ibuprofen arginine compositions in the Chinese patent of CN 1237964C, and concrete grammar is following:
The first step (granulation stage): with 62.3 gram polyvinylpyrrolidones (PVP) process 7% grams per milliliter 890 milliliters of PVP alcoholic solution, 4.8g is restrained 60 milliliters of the HPMC aqueous solutions that hydroxypropyl emthylcellulose (HPMC) is processed 8% grams per milliliter; With principal agent ibuprofen arginine 740g, mannitol 1000g, sucrose 955g, 890 milliliters of 7% grams per milliliter PVP alcoholic solution, 60 milliliters of abundant mix homogeneously of 8% grams per milliliter HPMC aqueous solution; Cross 60 mesh sieves, for use.
Second step (coating stage)
The preparation of coating solution:
A, the 529g sodium bicarbonate is dissolved in obtains solution in the appropriate amount of purified water;
B, 15g silicon dioxide and 200g ethyl cellulose joined be stirred in the ethanol of 180ml and with mixture and form homodisperse liquid;
C, step a gained solution and step b gained dispersion liquid are mixed, continue to stir and obtain coating solution.
Concrete coated granule prepares through following method: the granule that first step gained is for use joins the bottom of fluidized bed plant and granule is remained under 20～40 ℃ the condition, then above-mentioned coating solution is sprayed onto on the ibuprofen arginine bed with spray pattern.Make the ibuprofen arginine granule.
The result
Arginine Ibuprofen granule and ibuprofen arginine granule that embodiment 2～6 and Comparative Examples 1～5 are made respectively carry out quality inspection by two appendix I of Chinese Pharmacopoeia version in 2010 rules of preparations IN, concrete assay such as table 6.
Table 6
Get embodiment 6 gained granules and keep sample for a long time, investigate the result and see table 7.
Table 7
Conclusion: can know by above result; Arginine Ibuprofen granule each item index of the present invention all meets each item regulation (two appendix I of Chinese Pharmacopoeia version in 2010 rules of preparations IN) relevant under the granule item, like melting, granularity, content, mouthfeel, flowability etc.Long-term placement character does not change, stable in properties, and nonhygroscopic, mouthfeel remains unchanged, and content is not seen minimizing.Taste masked agent and correctives, flavoring agent have been added among the embodiment 2～6; Make the granule mouthfeel better, and do not add taste masked agent or correctives in the Comparative Examples 1～4, mouthfeel is peppery or tasteless; So the reliability and the controllability of explanation the inventive method; And technology of the present invention is simple, the cycle short, and no especial equipment requirements is more suitable in suitability for industrialized production.
Though, the present invention has been done detailed description in the preceding text with general explanation and specific embodiments, on basis of the present invention, can to some modifications of do or improvement, this will be apparent to those skilled in the art.Therefore, these modifications or the improvement on the basis of not departing from spirit of the present invention, made all belong to the scope that requirement of the present invention is protected.
Claims (10)
1. an arginine Ibuprofen granule is characterized in that, is grouped into by following one-tenth by weight:
1 part of arginine Ibuprofen;
1～50 part of filler;
0.1～50 part of taste masked agent;
0.1～10 part of binding agent;
0.01～1 part of correctives;
0.01～1 part of flavoring agent.
2. arginine Ibuprofen granule according to claim 1 is characterized in that, is grouped into by following one-tenth by weight:
1 part of arginine Ibuprofen;
2～25 parts of filleies;
1～25 part of taste masked agent;
0.4～5 part of binding agent;
0.01～0.5 part of correctives;
0.01～0.5 part of flavoring agent;
Preferably be grouped into by following one-tenth by weight:
1 part of arginine Ibuprofen;
2～10 parts of filleies;
2～10 parts of taste masked agent;
0.4～2.5 part of binding agent;
0.02～0.3 part of correctives;
0.01～0.1 part of flavoring agent.
3. arginine Ibuprofen granule according to claim 1 and 2 is characterized in that said filler is selected from one or more in lactose, sucrose, mannitol, the maltodextrin.
4. arginine Ibuprofen granule according to claim 1 and 2 is characterized in that, said taste masked agent is selected from one or more in betacyclodextrin, hypromellose K4M, carboxymethylstach sodium, the 30 POVIDONE K 30 BP/USP 30.
5. arginine Ibuprofen granule according to claim 1 and 2 is characterized in that, said binding agent is selected from the ethanol water of hypromellose K4M, the ethanol water or the ethanol water of 30 POVIDONE K 30 BP/USP 30; Wherein, the concentration expressed in percentage by volume of ethanol water is 40～95%, and the mass percentage concentration of hypromellose K4M, 30 POVIDONE K 30 BP/USP 30 is 2～10%.
6. arginine Ibuprofen granule according to claim 1 and 2 is characterized in that said correctives is selected from sodium cyclamate, aspartame or sucralose.
7. arginine Ibuprofen granule according to claim 1 and 2 is characterized in that said flavoring agent is an essence, is preferably orange essence or strawberry essence.
8. the method for preparing of each said arginine Ibuprofen granule of claim 1-7; It is characterized in that; At first with correctives and filler mix homogeneously; With gained mixture and arginine Ibuprofen, taste masked agent mix homogeneously, add binding agent then and granulate again, promptly get with the flavoring agent mixing more at last.
9. method for preparing according to claim 8 is characterized in that, said pelletization is: add binding agent and process soft material, adopt 18 mesh sieves to granulate, and drying, last 16 mesh sieve granulate promptly get.
10. method for preparing according to claim 9 is characterized in that, said baking temperature is 50～90 ℃, preferred 60～80 ℃; Be 1～5h drying time.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100679850A CN102626394A (en) | 2012-03-15 | 2012-03-15 | Arginine ibuprofen granules and preparation method thereof |
| CN201210281291.7A CN102961371B (en) | 2012-03-15 | 2012-08-08 | A kind of ibuprofen arginine granule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100679850A CN102626394A (en) | 2012-03-15 | 2012-03-15 | Arginine ibuprofen granules and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102626394A true CN102626394A (en) | 2012-08-08 |
Family
ID=46584902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100679850A Withdrawn CN102626394A (en) | 2012-03-15 | 2012-03-15 | Arginine ibuprofen granules and preparation method thereof |
| CN201210281291.7A Active CN102961371B (en) | 2012-03-15 | 2012-08-08 | A kind of ibuprofen arginine granule and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210281291.7A Active CN102961371B (en) | 2012-03-15 | 2012-08-08 | A kind of ibuprofen arginine granule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN102626394A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104902876A (en) * | 2012-11-30 | 2015-09-09 | 葛兰素史克公司 | Novel pharmaceutical composition |
| CN108926717A (en) * | 2018-07-13 | 2018-12-04 | 大连医诺生物股份有限公司 | A kind of arginine particle and preparation method thereof |
| CN109381426A (en) * | 2017-08-11 | 2019-02-26 | 北京人福军威医药技术开发有限公司 | A kind of ibuprofen oral spray and preparation method thereof |
| CN112137966A (en) * | 2020-10-28 | 2020-12-29 | 哈药集团技术中心 | Ibuprofen granule and preparation method thereof |
| CN117257913A (en) * | 2023-11-23 | 2023-12-22 | 江西中医药大学附属医院 | Lung-warming chemical fiber granule and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR2021016324A2 (en) * | 2021-10-20 | 2021-11-22 | Ardi Farma Ilac Pazarlama Tic Ltd Sti | TABLET FORMULATION FOR TASTE MASKING OF ACTIVE INGREDIENTS WITH PICTURE |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856331B (en) * | 2010-05-20 | 2012-07-04 | 海南新中正制药有限公司 | Arginine (s)-ibuprofen granules and preparation method thereof |
-
2012
- 2012-03-15 CN CN2012100679850A patent/CN102626394A/en not_active Withdrawn
- 2012-08-08 CN CN201210281291.7A patent/CN102961371B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104902876A (en) * | 2012-11-30 | 2015-09-09 | 葛兰素史克公司 | Novel pharmaceutical composition |
| CN104902876B (en) * | 2012-11-30 | 2018-01-19 | 葛兰素史克公司 | New pharmaceutical composition |
| CN107970214A (en) * | 2012-11-30 | 2018-05-01 | 葛兰素史克公司 | New pharmaceutical composition |
| CN109381426A (en) * | 2017-08-11 | 2019-02-26 | 北京人福军威医药技术开发有限公司 | A kind of ibuprofen oral spray and preparation method thereof |
| CN108926717A (en) * | 2018-07-13 | 2018-12-04 | 大连医诺生物股份有限公司 | A kind of arginine particle and preparation method thereof |
| CN112137966A (en) * | 2020-10-28 | 2020-12-29 | 哈药集团技术中心 | Ibuprofen granule and preparation method thereof |
| CN117257913A (en) * | 2023-11-23 | 2023-12-22 | 江西中医药大学附属医院 | Lung-warming chemical fiber granule and preparation method thereof |
| CN117257913B (en) * | 2023-11-23 | 2024-01-26 | 江西中医药大学附属医院 | Lung-warming chemical fiber granule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102961371B (en) | 2015-08-12 |
| CN102961371A (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102626394A (en) | Arginine ibuprofen granules and preparation method thereof | |
| EP2005945A2 (en) | Oseltamivir phosphate granule and preparation mehtod thereof | |
| CN107625786A (en) | A kind of calcium carbonate vitamin D3Composition and its anhydrous swallow particle | |
| CN101198319A (en) | Granular preparation containing biguanide compound | |
| CN102860985B (en) | Tebipenem pivoxil oral preparation and preparation method thereof | |
| CN104546806A (en) | Oral cavity instant film containing risperidone and preparation method for oral cavity instant film | |
| CN102327244B (en) | Ambroxol hydrochloride orally disintegrating tablet and preparation method thereof | |
| CN101152155A (en) | Hydrochloric acid Ivabradine solid pharmaceutical composition and method for preparing the same | |
| CN116098864B (en) | Linaclotide dry suspension and preparation method thereof | |
| CN101856331B (en) | Arginine (s)-ibuprofen granules and preparation method thereof | |
| CN112826798A (en) | Ibuprofen pharmaceutical composition, preparation method and application | |
| CN111617042A (en) | Composite calcium carbonate vitamin D3Water-free swallow granule and preparation method thereof | |
| JP5201837B2 (en) | Orally disintegrating tablets | |
| CN107149594B (en) | Calcium acetate taste-masking granules and preparation method thereof | |
| CN103156812A (en) | Dextrorotation ibuprofen dried suspension and preparation method thereof | |
| CN104606145B (en) | ibuprofen granule and preparation method thereof | |
| CN103816123B (en) | A kind of CEFUROXIME AXETIL composition and method of making the same | |
| CN103721267A (en) | Composition containing desloratadine citrate disodium | |
| CN1771915A (en) | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn | |
| CN106267209A (en) | Low dosage non-steroidal anti-inflammatory class pharmaceutical composition and preparation technology thereof | |
| CN102488689B (en) | Compound zinc gluconateand ibuprofen granule capable of curing cold and preparation method thereof | |
| KR101067224B1 (en) | Controlled releasing syrup containing ibuprofen and its manufacturing method | |
| CN104434860A (en) | Ambroxol hydrochloride osmotic pump type pharmaceutical composition prepared by inclusion process | |
| CN100360128C (en) | Huperzine-A oral cavity disintegration tablet and its preparation method | |
| CN104771365A (en) | Dexibuprofen dry suspension agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Open date: 20120905 |